NASDAQ:TCON

TRACON Pharmaceuticals Stock Forecast, Price & News

$10.70

+0.09 (+0.85 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.03

Now: $10.70▼

$11.10

50-Day Range

$7.60

MA: $9.56▼

$11.70

52-Week Range

$0.95

Now: $10.70▼

$12.20

Volume421,558 shs

Average Volume571,975 shs

Market Capitalization$146.43 million

P/E RatioN/A

Dividend YieldN/A

Beta2.02

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clinical trial to treat solid tumors, Phase I/II to treat solid tumors and lymphomas, and Phase I trial to treat lung cancer; TRC253, a small molecule, which is in a Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Janssen Pharmaceutica N.V. for the development of TRC253; Santen Pharmaceutical Co. Ltd. for the development of carotuximab products for ophthalmology indications; Roswell Park Cancer Institute and Health Research Inc.; Case Western Reserve University; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

221st out of 1,922 stocks

Biological Products, Except Diagnostic Industry

27th out of 177 stocks

2.5 Analyst's Opinion

Consensus Rating
TRACON Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, TRACON Pharmaceuticals has a forecasted upside of 12.1% from its current price of $10.70.
Amount of Analyst Coverage
TRACON Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
TRACON Pharmaceuticals has received 248 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TRACON Pharmaceuticals has received 199 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TRACON Pharmaceuticals has received 55.48% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TRACON Pharmaceuticals and other stocks. Vote “Outperform” if you believe TCON will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCON will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TRACON Pharmaceuticals does not currently pay a dividend.
Dividend Growth
TRACON Pharmaceuticals does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TRACON Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,010,559.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 23.30% of the stock of TRACON Pharmaceuticals is held by insiders.
Percentage Held by Institutions
42.03% of the stock of TRACON Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for TRACON Pharmaceuticals are expected to grow in the coming year, from ($1.92) to ($1.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TRACON Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TRACON Pharmaceuticals is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TRACON Pharmaceuticals has a P/B Ratio of 15.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TCON

Previous Symbol

CUSIPN/A

CIK1394319

Webwww.traconpharma.com

Phone858-550-0780

Employees19

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.13

Current Ratio2.76

Quick Ratio2.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$3 million

Price / Sales48.81

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.67 per share

Price / Book15.97

Profitability

EPS (Most Recent Fiscal Year)($7.47)

Net Income$-22,670,000.00

Net MarginsN/A

Return on Equity-273.66%

Return on Assets-84.56%

Miscellaneous

Outstanding Shares13,685,000

Market Cap$146.43 million

Next Earnings Date2/25/2021 (Estimated)

OptionableNot Optionable

$10.70

+0.09 (+0.85 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive TCON News and Ratings via Email

Sign-up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.

TRACON Pharmaceuticals (NASDAQ:TCON) Frequently Asked Questions

How has TRACON Pharmaceuticals' stock price been impacted by COVID-19?

TRACON Pharmaceuticals' stock was trading at $1.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TCON stock has increased by 658.9% and is now trading at $10.70.
View which stocks have been most impacted by COVID-19.

Is TRACON Pharmaceuticals a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRACON Pharmaceuticals stock.
View analyst ratings for TRACON Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than TRACON Pharmaceuticals?

Wall Street analysts have given TRACON Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TRACON Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is TRACON Pharmaceuticals' next earnings date?

TRACON Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for TRACON Pharmaceuticals.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) issued its quarterly earnings results on Tuesday, November, 10th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.65) by $0.27.
View TRACON Pharmaceuticals' earnings history.

What price target have analysts set for TCON?

1 analysts have issued 1 year price targets for TRACON Pharmaceuticals' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate TRACON Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts' price targets for TRACON Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Are investors shorting TRACON Pharmaceuticals?

TRACON Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 179,300 shares, an increase of 34.0% from the December 15th total of 133,800 shares. Based on an average trading volume of 738,200 shares, the short-interest ratio is currently 0.2 days. Currently, 1.4% of the shares of the stock are sold short.
View TRACON Pharmaceuticals' Short Interest.

Who are some of TRACON Pharmaceuticals' key competitors?

Some companies that are related to TRACON Pharmaceuticals include MeiraGTx (MGTX), Poseida Therapeutics (PSTX), AVROBIO (AVRO), Codiak BioSciences (CDAK), Harpoon Therapeutics (HARP), Oyster Point Pharma (OYST), Fusion Pharmaceuticals (FUSN), Jounce Therapeutics (JNCE), Surface Oncology (SURF), Opthea (OPT), Freeline Therapeutics (FRLN), Autolus Therapeutics (AUTL), CASI Pharmaceuticals (CASI), Solid Biosciences (SLDB) and Aptose Biosciences (APTO).
View all of TCON's competitors.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

Who are TRACON Pharmaceuticals' key executives?

TRACON Pharmaceuticals' management team includes the following people:

Dr. Charles P. Theuer, CEO, Pres & Director (Age 56, Pay $826.76k)
Mr. Scott B. Brown CPA, M.S., Chief Accounting Officer & Head of Fin. (Age 39, Pay $445.04k)
Mr. Mark C. Wiggins M.B.A., Chief Bus. Officer (Age 64, Pay $501.84k)
Ms. Bonne Adams, Exec. VP of Clinical Operations (Age 43)
Mr. Shahe Garabedian, Sr. VP & Head of Quality Assurance
Dr. James L. Freddo, Chief Medical Officer (Age 65)

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel served as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vigilare Wealth Management (0.10%). Company insiders that own TRACON Pharmaceuticals stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc and Saundra L Pelletier.
View institutional ownership trends for TRACON Pharmaceuticals.

Which major investors are selling TRACON Pharmaceuticals stock?

TCON stock was sold by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for TRACON Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $10.70.

How big of a company is TRACON Pharmaceuticals?

TRACON Pharmaceuticals has a market capitalization of $146.43 million and generates $3 million in revenue each year. The biopharmaceutical company earns $-22,670,000.00 in net income (profit) each year or ($7.47) on an earnings per share basis. TRACON Pharmaceuticals employs 19 workers across the globe.

What is TRACON Pharmaceuticals' official website?

The official website for TRACON Pharmaceuticals is www.traconpharma.com.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The biopharmaceutical company can be reached via phone at 858-550-0780 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here